Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Asia-Pacific CRO Novotech has acquired Australasian specialist CRO Clinical Network Services (CNS), with a mutual mission to expand services
SYDNEY, Oct 19, 2018 - (ACN Newswire) - Novotech, the largest Asia-Pacific-based CRO, has acquired Australasian specialist CRO Clinical Network Services (CNS), as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials. Both companies will continue to retain their separate brands and identities.
Early phase CNS clients, wishing to advance into later phase regional trials, can tap into Novotech's Asia-Pacific expertise backed by 10 partnership agreements with leading hospitals and medical institutions, offering access to 1.4 billion people living in urban areas across the region. Novotech has 400+ staff across Asia-Pacific and business development offices in the USA. CNS has more than 140 staff in Australia, New Zealand and the USA.
As part of the deal, clients can access leading services from both groups, including the CNS BioDesk, which provides early stage product development advice including toxicology, CMC and FDA/EMA regulatory consulting and interactions; and Novotech's advanced regional IT infrastructure, to support their clinical research programs.
Novotech CEO John Moller said:
"Biopharma clients should know this acquisition is a bringing together of the highest quality CROs in the region. Very importantly, we have developed remarkably similar company cultures, and I know the teams are excited about the opportunity of working together.
"Novotech and CNS will continue to operate under separate brands with CNS specialising in early phase non-oncology clinical trials across Australia and New Zealand, and Novotech specialising in regional Asia-Pacific and global project delivery across all phases.
"Our Asia-Pacific in-country relationships enable a comprehensive understanding of local regulatory requirements and changes, access to leading investigators, strong site connections, and accessible patient populations to deliver success for our clients within timelines and budgets."
CNS Managing Director Russ Neal commented:
"Early phase research in Australasia has seen incredible growth over the last 6-7 years and CNS is proud to be a significant part of this proven capability. As our clients have experienced success with us, we have often wished we had the international reach to continue supporting them.
"This truly complimentary association with Novotech now means that we are able to offer our clients access to Novotech's Asia-Pacific experience and expertise in later phase regional or global trials. On the other hand, Novotech clients can access our highly regarded global product development and regulatory affairs consultancy team, BioDesk, based out of Washington DC, London and Australia"
CNS COO and Executive Director Gabrielle McKee further added:
"CNS clients will also benefit from many of Novotech's strengths, including IT infrastructure and specialist functions such as legal, learning and development, marketing and analytics,. and particularly exciting, CNS and Novotech offer our clients one of the most experienced and knowledgeable biometrics teams in the region, with 70 staff in the combined unit."
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia-Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia-Pacific presence includes running clinical trials in all key regional markets, with a worldwide reach through the company's network of strategic partners.
About Clinical Network Services (CNS) - https://clinical.net.au/
Clinical Network Services (CNS) is an integrated service group focused on product development. Headquartered in Australia, with offices in New Zealand, the UK and the USA, CNS creates value for small to medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service, integrating BioDesk, an intelligent global product development and regulatory affairs consultancy, with its committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS' regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval.
CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables it to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
USA: +1 415 951 3228
AUS: +61 2 8218 2144
ASIA: +65 3159 3427
Source: Clinical Network Services (CNS)
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Fujitsu Launches 14 New Models of Enterprise Notebooks, Tablets and Workstations Optimized for Remote Work
May 26, 2020 11:10 JST
Fujitsu Develops AI-Video Recognition Technology to Promote Hand Washing Etiquette and Hygiene in the Workplace
May 26, 2020 10:34 JST
Mitsubishi Motors Joins OPEN COVID-19 DECLARATION
May 26, 2020 09:34 JST
Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC
May 25, 2020 10:44 JST
Mazda Begins Providing, Virtual Racing Car, Mazda RX-Vision GT3 Concept Online
May 22, 2020 14:26 JST
'e5 Consortium' Established to Promote Zero-Emission Electric Vessel
May 21, 2020 15:34 JST
TOYOTA GAZOO Racing Decides Not to Participate in 2020 Edition of Nurburgring 24 Hours
May 21, 2020 14:19 JST
Fujitsu RunMyProcess Drives Next Phase of Digital Transformation in Business Processes with DigitalSuite ProcessModeler
May 21, 2020 09:00 JST
MHPS Captures Global Gas Turbine Market Share Leadership Again
May 20, 2020 10:09 JST
Hitachi Awarded Contract to Supply, Install 300 Lifts at HDB Blocks in Singapore
May 19, 2020 11:57 JST
DENSO, Global Mobility Service to Support Delivery of COVID-19 Test Kits in Indonesia
May 18, 2020 17:36 JST
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18, 2020 13:33 JST
Hitachi to Provide $1 Million in Loans through Kiva to Businesses in Need around the Globe, Affected by the Spread of the COVID-19
May 18, 2020 13:24 JST
Toyota's Adjustments to Domestic Production in June 2020 (as of May 15)
May 15, 2020 17:01 JST
Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
May 15, 2020 14:10 JST
Fujitsu and Accenture Collaboration Accelerates Reliable Blockchain Interoperability
May 15, 2020 10:11 JST
Mazda Releases FY March 2020 Full Year Financial Results
May 14, 2020 17:01 JST
Fujitsu Sets Out the 'Fujitsu Technology and Service Vision 2020'
May 14, 2020 15:53 JST
Notice of Agreement for the Merger through Absorption (Simplified Absorption-type Merger) of a Consolidated Subsidiary of Fujitsu Limited
May 14, 2020 15:46 JST
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14, 2020 09:22 JST